FDA approval of Eli Lilly’s Zepbound is a win for patients as Ozempic competitors boom
Pharmaceutical companies are now racing to develop anti-obesity drugs, and experts say that could drive supply up and price down.
The U.S. Food and Drug Administration (FDA) announced Wednesday that it has approved Zepbound, an injectable treatment manufactured by Eli Lilly for chronic weight management. The approval of Zepbound, which is similar to Ozempic, adds to the growing list of medications designed to help treat people with obesity, a condition that affects about two out of five Americans.
Read Full Story